Loncipoetin alfa

罗赛促红素α

Report date: 2026/04/08 20:02:35

Base Information

Drug NameLoncipoetin alfa
Drug Alias Name长效促红素SSS06Pegerythropoietin重组红细胞生成刺激蛋白注射液（rESP,CHO细胞）PEG EPOPegylated erythropoietin (3SBio) +[20] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaKidney Failure, ChronicRenal Insufficiency, Chronic +[6] 
Global Approved IndicationsAnemiaRenal Insufficiency
Approved Indications in ChinaAnemiaRenal Insufficiency
Original Approved Country/TerritoryMainland China
Original Approved Date2026/03/17
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenyang Sunshine Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangdong Sansheng Pharmaceutical Co LtdShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesShenzhen Sciprogen Bio-Pharmaceutical Co Ltd
Active IndicationsAnemiaRenal InsufficiencyNephrosis +[4] 
Inactive IndicationsKidney Failure, ChronicRenal Insufficiency, Chronic

Other Information

ATC CodeB03XA01
Related LinksN/A